MIROMATRIX MEDICAL INC (MIRO) Stock Price & Overview

NASDAQ:MIROUS60471P1084

Current stock price

3.39 USD
+0.02 (+0.59%)
At close:
3.39 USD
0 (0%)
After Hours:

The current stock price of MIRO is 3.39 USD. Today MIRO is up by 0.59%. In the past month the price increased by 1.5%. In the past year, price increased by 17.71%.

MIRO Key Statistics

52-Week Range0.9065 - 3.73
Current MIRO stock price positioned within its 52-week range.
1-Month Range3.3 - 3.53
Current MIRO stock price positioned within its 1-month range.
Market Cap
92.954M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.14
Dividend Yield
N/A

MIRO Stock Performance

Today
+0.59%
1 Week
-0.29%
1 Month
+1.50%
3 Months
+149.27%
Longer-term
6 Months +111.87%
1 Year +17.71%
2 Years -27.72%
3 Years N/A
5 Years N/A
10 Years N/A

MIRO Stock Chart

MIROMATRIX MEDICAL INC / MIRO Daily stock chart

MIRO Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to MIRO. When comparing the yearly performance of all stocks, MIRO is one of the better performing stocks in the market, outperforming 96.98% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MIRO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MIRO. MIRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MIRO Earnings

Next Earnings DateN/A
Last Earnings DateNov 14, 2023
PeriodQ3 / 2023
EPS Reported-$0.24
Revenue Reported
EPS Surprise -12.04%
Revenue Surprise 180.11%

MIRO Forecast & Estimates

8 analysts have analysed MIRO and the average price target is 3.19 USD. This implies a price decrease of -5.97% is expected in the next year compared to the current price of 3.39.

For the next year, analysts expect an EPS growth of 32.47% and a revenue growth -6.67% for MIRO


Analysts
Analysts80
Price Target3.19 (-5.9%)
EPS Next Y32.47%
Revenue Next Year-6.67%

MIRO Groups

Sector & Classification

Index Membership

MIRO Financial Highlights

Over the last trailing twelve months MIRO reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 17.99% compared to the year before.


Income Statements
Revenue(TTM)960.00K
Net Income(TTM)-27.41M
Industry RankSector Rank
PM (TTM) N/A
ROA -117.04%
ROE -176.38%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%35.14%
Sales Q2Q%0%
EPS 1Y (TTM)17.99%
Revenue 1Y (TTM)3100%

MIRO Ownership

Ownership
Inst Owners22.32%
Shares27.42M
Float21.01M
Ins Owners108.14%
Short Float %N/A
Short RatioN/A

About MIRO

Company Profile

MIRO logo image Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company is headquartered in Eden Prairie, Minnesota and currently employs 76 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.

Company Info

IPO: 2021-06-24

MIROMATRIX MEDICAL INC

6455 Flying Cloud Drive, Suite 107

Eden Prairie MINNESOTA US

CEO: Jeff Ross

Employees: 76

MIRO Company Website

Phone: 16122027026

MIROMATRIX MEDICAL INC / MIRO FAQ

What does MIROMATRIX MEDICAL INC do?

Miromatrix Medical, Inc. operates as a biotechnology company, which engages in the development of biological human organs to solve the chronic shortage of transplantable organs. The company is headquartered in Eden Prairie, Minnesota and currently employs 76 full-time employees. The company went IPO on 2021-06-24. The firm is engaged in providing the technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company’s technology platform uses a two-step method of decellularization and recellularization. Its development focus is on bioengineering livers and kidneys, and its technology platform is also applicable to bioengineering other organs, including hearts, lungs, and pancreas. Decellularization is a process that is designed to remove porcine cells from the organs obtained from pigs to create a purified acellular extracellular matrix (ECM). Its perfusion process purifies the organs while preserving the mechanical structures and vascular networks. Recellularization is a process that incorporates perfusion to re-seed the ECM with unmodified human cells inside individual bioreactors. Its product pipeline includes miroliverelap, mirokidney, miroliver, miroheart, mirolung and miropancreas.


What is the stock price of MIROMATRIX MEDICAL INC today?

The current stock price of MIRO is 3.39 USD. The price increased by 0.59% in the last trading session.


Does MIROMATRIX MEDICAL INC pay dividends?

MIRO does not pay a dividend.


How is the ChartMill rating for MIROMATRIX MEDICAL INC?

MIRO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What do analysts say about MIROMATRIX MEDICAL INC (MIRO) stock?

8 analysts have analysed MIRO and the average price target is 3.19 USD. This implies a price decrease of -5.97% is expected in the next year compared to the current price of 3.39.


What is the Price/Earnings (PE) ratio of MIROMATRIX MEDICAL INC (MIRO)?

MIROMATRIX MEDICAL INC (MIRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).


Would investing in MIROMATRIX MEDICAL INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MIRO.